Organicell Regenerative Medicine, Inc. announce that the long COVID Clinical Trial is officially active with enrollment. Organicell has treated 18 people for COVID with Zofin under the guidance of the FDA's Emergency Investigational New Drug (eIND) program. The Company has also treated 10 patients under an FDA approved IND expanded access trial on Moderate COVID, and 8 patients under an FDA approved IND for Moderate to Severe COVID.

Sinnreich added "Organicell has published the results of the patients treated with Zofin and the data is compelling. Organicell's science team has been working with the CDC and accredited Universities to further demonstrate the science to get Zofin into the hands of the masses.